Nothing Special   »   [go: up one dir, main page]

MX348197B - Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos. - Google Patents

Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos.

Info

Publication number
MX348197B
MX348197B MX2015002869A MX2015002869A MX348197B MX 348197 B MX348197 B MX 348197B MX 2015002869 A MX2015002869 A MX 2015002869A MX 2015002869 A MX2015002869 A MX 2015002869A MX 348197 B MX348197 B MX 348197B
Authority
MX
Mexico
Prior art keywords
disorders
cancer
diseases
treatment
pharmaceutical compositions
Prior art date
Application number
MX2015002869A
Other languages
English (en)
Inventor
Ramanan Vijayalakshmi
Sophie Tobias Irene
Specht Verwijs Dauntel
D Skwierczynski Raymond
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42697590&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX348197(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of MX348197B publication Critical patent/MX348197B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención proporciona nuevas composiciones farmacéuticas del compuesto de la fórmula (I): (ver Fórmula) o una sal farmacéuticamente aceptable del mismo, que son adecuadas para la producción a granel de una forma de dosificación farmacéutica oral; procesos para la producción de dicha forma de dosificación farmacéutica oral; y el uso de la composición farmacéutica para el tratamiento de pacientes que padecen o son propensos a padecer enfermedades, trastornos o afecciones que implican supervivencia, proliferación y migración de células, incluidos trastornos proliferativos inflamatorios crónicos, trastornos oculares proliferativos, trastornos proliferativos benignos y cáncer.
MX2015002869A 2009-07-31 2010-07-28 Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos. MX348197B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23021209P 2009-07-31 2009-07-31
PCT/US2010/002109 WO2011014248A1 (en) 2009-07-31 2010-07-28 Pharmaceutical compositions for the treatment of cancer and other diseases or disorders

Publications (1)

Publication Number Publication Date
MX348197B true MX348197B (es) 2017-06-05

Family

ID=42697590

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015002869A MX348197B (es) 2009-07-31 2010-07-28 Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos.
MX2012001196A MX2012001196A (es) 2009-07-31 2010-07-28 Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2012001196A MX2012001196A (es) 2009-07-31 2010-07-28 Composiciones farmaceuticas para el tratamiento del cancer y otras enfermedades o trastornos.

Country Status (30)

Country Link
US (3) US20110039826A1 (es)
EP (1) EP2459173B1 (es)
JP (2) JP2013500965A (es)
KR (1) KR101762285B1 (es)
CN (2) CN103893186B (es)
AR (1) AR077436A1 (es)
AU (1) AU2010276741B2 (es)
BR (1) BR112012002265B8 (es)
CA (1) CA2769531C (es)
CL (1) CL2012000261A1 (es)
CO (1) CO6612185A2 (es)
CR (1) CR20120084A (es)
EA (1) EA025277B1 (es)
EC (1) ECSP12011703A (es)
GE (1) GEP201606513B (es)
IL (1) IL217839A (es)
IN (1) IN2012DN01237A (es)
JO (1) JO3434B1 (es)
MA (1) MA33533B1 (es)
MX (2) MX348197B (es)
MY (1) MY174084A (es)
NZ (1) NZ598096A (es)
PE (1) PE20120788A1 (es)
SG (2) SG177751A1 (es)
TN (1) TN2012000046A1 (es)
TW (1) TWI522357B (es)
UA (1) UA110463C2 (es)
UY (1) UY32822A (es)
WO (1) WO2011014248A1 (es)
ZA (1) ZA201200944B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101792651B1 (ko) * 2004-05-14 2017-11-20 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물
CN102264368B (zh) * 2008-12-22 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂与抗cd20抗体的组合
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
TWI392514B (zh) * 2010-01-29 2013-04-11 Colgate Palmolive Co 具有高微生物效力之不含氟化物及陰離子表面活性劑的潔牙劑
CN102770024A (zh) 2010-02-19 2012-11-07 米伦纽姆医药公司 4-{[9-氯-7-(2-氟-6-甲氧基苯基)-5h-嘧啶并[5,4-d][2]苯并氮杂卓-2基]氨基}-2-甲氧基苯甲酸钠的结晶形式
AR086656A1 (es) 2011-06-03 2014-01-15 Millennium Pharm Inc Combinacion de inhibidores de mek e inhibidores selectivos de la quinasa aurora a
US20130303519A1 (en) 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN105209042B (zh) 2013-03-22 2019-03-08 米伦纽姆医药公司 催化性mtorc 1/2抑制剂与选择性极光a激酶抑制剂的组合
EP3076963A4 (en) 2013-12-06 2017-09-13 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd30 antibodies
WO2017015316A1 (en) 2015-07-21 2017-01-26 Millennium Pharmaceuticals, Inc. Administration of aurora kinase inhibitor and chemotherapeutic agents
USD797120S1 (en) 2015-08-28 2017-09-12 Samsung Electronics Co., Ltd. Display screen or portion thereof with graphical user interface

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5747487A (en) * 1993-07-29 1998-05-05 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
AU5330698A (en) 1996-12-23 1998-07-17 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
WO2001010462A1 (en) 1999-08-11 2001-02-15 Idec Pharmaceuticals Corporation Treatment of patients having non-hodgkins lymphoma with bone marrow involvement with anti-cd20 antibodies
EP1315484A1 (en) * 2000-03-24 2003-06-04 Baker Norton Pharmaceuticals, Inc. Taxane-based compositions and methods of use
US6982253B2 (en) * 2002-06-05 2006-01-03 Supergen, Inc. Liquid formulation of decitabine and use of the same
KR101792651B1 (ko) * 2004-05-14 2017-11-20 밀레니엄 파머슈티컬스 인코퍼레이티드 아우로라 키나아제의 억제에 의해 유사분열 진행을 억제하기 위한 화합물 및 그 화합물을 포함하는 약학적 조성물
US20070104785A1 (en) * 2005-07-29 2007-05-10 Navale Suryakant V Tablets of linezolid form iii and processes for their preparation
WO2007076348A2 (en) * 2005-12-23 2007-07-05 Smithkline Beecham Corporation Azaindole inhibitors of aurora kinases
JP2009542664A (ja) 2006-06-30 2009-12-03 シェーリング コーポレイション Ｐ５３活性を増大させる置換されたピペリジンの使用の方法
EP2046292B1 (en) * 2006-07-21 2010-03-03 Novartis AG Formulations for benzimidazolyl pyridyl ethers
US7718648B2 (en) 2006-08-09 2010-05-18 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
US20090203671A1 (en) * 2007-11-27 2009-08-13 Abbott Laboratories Method of treating cancer
CN102264368B (zh) * 2008-12-22 2014-09-10 米伦纽姆医药公司 极光激酶抑制剂与抗cd20抗体的组合
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
CN102770024A (zh) * 2010-02-19 2012-11-07 米伦纽姆医药公司 4-{[9-氯-7-(2-氟-6-甲氧基苯基)-5h-嘧啶并[5,4-d][2]苯并氮杂卓-2基]氨基}-2-甲氧基苯甲酸钠的结晶形式

Also Published As

Publication number Publication date
CA2769531A1 (en) 2011-02-03
ECSP12011703A (es) 2012-03-30
EP2459173B1 (en) 2018-02-28
ZA201200944B (en) 2015-07-29
SG177751A1 (en) 2012-02-28
EA025277B1 (ru) 2016-12-30
EP2459173A1 (en) 2012-06-06
US9127011B2 (en) 2015-09-08
JP6014695B2 (ja) 2016-10-25
KR20120053008A (ko) 2012-05-24
IN2012DN01237A (es) 2015-05-15
CO6612185A2 (es) 2013-02-01
MX2012001196A (es) 2012-03-14
BR112012002265A2 (pt) 2016-06-14
CN102548539A (zh) 2012-07-04
BR112012002265B8 (pt) 2021-05-25
NZ598096A (en) 2014-05-30
UA110463C2 (ru) 2016-01-12
CN103893186A (zh) 2014-07-02
EA201270205A1 (ru) 2012-07-30
MY174084A (en) 2020-03-09
JP2015091877A (ja) 2015-05-14
TW201107331A (en) 2011-03-01
JO3434B1 (ar) 2019-10-20
CL2012000261A1 (es) 2012-08-03
WO2011014248A1 (en) 2011-02-03
US20160158244A1 (en) 2016-06-09
IL217839A (en) 2017-01-31
GEP201606513B (en) 2016-07-25
TWI522357B (zh) 2016-02-21
PE20120788A1 (es) 2012-07-22
IL217839A0 (en) 2012-03-29
AR077436A1 (es) 2011-08-24
AU2010276741A1 (en) 2012-03-01
US9504693B2 (en) 2016-11-29
JP2013500965A (ja) 2013-01-10
MA33533B1 (fr) 2012-08-01
BR112012002265B1 (pt) 2021-01-12
CN103893186B (zh) 2019-07-09
CR20120084A (es) 2012-06-01
KR101762285B1 (ko) 2017-07-28
CA2769531C (en) 2017-11-07
SG10201404483VA (en) 2014-10-30
UY32822A (es) 2011-01-31
AU2010276741B2 (en) 2016-07-14
US20110039826A1 (en) 2011-02-17
TN2012000046A1 (en) 2013-09-19
US20140073630A1 (en) 2014-03-13

Similar Documents

Publication Publication Date Title
TN2012000046A1 (en) Pharmaceutical compositions for the treatment of cancer and other diseases or disorfers
MX2013012588A (es) Inhibidores de cinasa.
EA031157B9 (ru) Вводимая перорально кортикостероидная композиция
NZ608116A (en) Triazine-oxadiazoles
MX2009006543A (es) Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
MX2010007683A (es) Derivados heterociclicos fusionados y metodos de uso como inhibidores de c-met.
UA104489C2 (uk) Сполуки для лікування дисліпідемії та споріднених хвороб
GEP20135744B (en) Quinuclidine carbonate derivatives and medicinal compositions containing the same
MX2009009153A (es) Pirano-pirazol-aminas.
EA201171088A1 (ru) Лечение дискинезии при различных расстройствах
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
GEP20135806B (en) Lactams as beta secretase inhibitors
MX2009009154A (es) Derivados de espiro-pirano-pirazol.
IN2012DN03042A (es)
MX2014002394A (es) Inhibidores de rock suaves, novedosos.
MX2012013879A (es) Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas.
MX2013006768A (es) Moduladores de receptor de glucagon.
MX2011012384A (es) Derivados nitrilo y sus usos y composiciones farmaceuticas.
IN2013DN02555A (es)
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MY182553A (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
MX2014003455A (es) Derivados de metanosulfonamida sustituidos con arilo o n-heteroarilo como ligandos de receptor vanilloide.
MX2011008857A (es) Derivados de oxiindol con actividad agonistica del receptor de motilina.
MX2010004620A (es) Derivados de benzomorfolina y metodos de uso.
GEP20125640B (en) Phenanthrenone compounds, compositions containing them and use thereof